Functional analysis of intron 8 and 3′ UTR variable number of tandem repeats of SLC6A3: Differential activity of intron 8 variants

Pharmacogenomics Journal

Volumn 10, Issue 5, 2010, Pages 442-447

  Hill, M ^a   Anney, R J L ^a   Gill, M ^a   Hawi, Z ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

ADHD; dopamine transporter; functional variant; methylphenidate

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; DOPAMINE TRANSPORTER; FORSKOLIN; PROTEIN SLC6A3; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; ATTENTION DEFICIT DISORDER; CELL STIMULATION; GENE CONSTRUCT; GENE INDUCTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTRON; PRIORITY JOURNAL; VARIABLE NUMBER OF TANDEM REPEAT;

3' UNTRANSLATED REGIONS; ALLELES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FORSKOLIN; GENES, REPORTER; GENETIC VECTORS; HUMANS; INTRONS; LUCIFERASES; METHYLPHENIDATE; MINISATELLITE REPEATS; PIPERAZINES; TRANSFECTION;

EID: 77957158276     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.66     Document Type: Article

References (24)

1. Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: The Prevalence of DSM-IV Disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 1203-1211.
2. Poeta LS, Rosa Neto F. (Epidemiological study on symptoms of attention deficit/hyperactivity disorder and behavior disorders in public schools of Florianopolis/SC using the EDAH). Rev Bras Psiquiatr 2004; 26: 150-155.
3. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
4. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104-1106.
5. Cook Jr EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993-998.
6. Brookes KJ, Mill J, Guindalini C, Curran S, Xu X, Knight J et al. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 2006; 63: 74-81.
7. Asherson P, Brookes K, Franke B, Chen W, Gill M, Ebstein RP et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. Am J Psychiatry 2007; 164: 674-677.
8. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38: 1474-1477.
9. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics 2002; 12: 497-499.
10. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I et al. Association of the 480bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 2003; 121: 50-54.
11. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005; 30: 1374-1382.
12. Langley K, Turic D, Peirce TR, Mills S, Van Den Bree MB, Owen MJ et al. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet 2005; 139: 7-10.
13. O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Geno-mics 2007; 17: 61-67.
14. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3 UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114: 975-979.
15. Mill J, Asherson P, Craig I, D'Souza UM. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005; 6: 3.
16. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001; 1: 152-156.
17. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 2006; 103: 4552-4557.
18. Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D'Souza UM. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1070-1078.
19. Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett 2005; 377: 106-109.
20. Sheehan JP, Palmer PE, Helm GA, Tuttle JB. MPP+induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. J Neurosci Res 1997; 48: 226-237.
21. Seo M, Kim Y, Lee YI, Kim SY, Ahn YM, Kang UG et al. Membrane depolarization stimulates the proliferation of SH-SY5Y human neuro-blastoma cells by increasing retinoblastoma protein (RB) phosphoryla-tion through the activation of cyclin-dependent kinase 2 (Cdk2). Neurosci Lett 2006; 404: 87-92.
22. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-2942.
23. Greenwood TA, Kelsoe JR. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003; 82: 511-520.
24. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.